KR102440162B1 - 안구 염증 병태의 치료에 사용하기 위한 인테그린 알파4 길항제를 포함하는 제약 조성물 - Google Patents

안구 염증 병태의 치료에 사용하기 위한 인테그린 알파4 길항제를 포함하는 제약 조성물 Download PDF

Info

Publication number
KR102440162B1
KR102440162B1 KR1020187003454A KR20187003454A KR102440162B1 KR 102440162 B1 KR102440162 B1 KR 102440162B1 KR 1020187003454 A KR1020187003454 A KR 1020187003454A KR 20187003454 A KR20187003454 A KR 20187003454A KR 102440162 B1 KR102440162 B1 KR 102440162B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
treatment
compound
certain embodiments
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187003454A
Other languages
English (en)
Korean (ko)
Other versions
KR20180041122A (ko
Inventor
아힘 한스-피터 크라우스
Original Assignee
악세로비젼, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 악세로비젼, 인크. filed Critical 악세로비젼, 인크.
Priority to KR1020227015200A priority Critical patent/KR20220062688A/ko
Publication of KR20180041122A publication Critical patent/KR20180041122A/ko
Application granted granted Critical
Publication of KR102440162B1 publication Critical patent/KR102440162B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020187003454A 2015-07-08 2016-07-07 안구 염증 병태의 치료에 사용하기 위한 인테그린 알파4 길항제를 포함하는 제약 조성물 Active KR102440162B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227015200A KR20220062688A (ko) 2015-07-08 2016-07-07 안구 염증 병태의 치료에 사용하기 위한 인테그린 알파4 길항제를 포함하는 제약 조성물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562189813P 2015-07-08 2015-07-08
US62/189,813 2015-07-08
PCT/IB2016/054073 WO2017006272A1 (en) 2015-07-08 2016-07-07 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227015200A Division KR20220062688A (ko) 2015-07-08 2016-07-07 안구 염증 병태의 치료에 사용하기 위한 인테그린 알파4 길항제를 포함하는 제약 조성물

Publications (2)

Publication Number Publication Date
KR20180041122A KR20180041122A (ko) 2018-04-23
KR102440162B1 true KR102440162B1 (ko) 2022-09-02

Family

ID=56373100

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187003454A Active KR102440162B1 (ko) 2015-07-08 2016-07-07 안구 염증 병태의 치료에 사용하기 위한 인테그린 알파4 길항제를 포함하는 제약 조성물
KR1020227015200A Ceased KR20220062688A (ko) 2015-07-08 2016-07-07 안구 염증 병태의 치료에 사용하기 위한 인테그린 알파4 길항제를 포함하는 제약 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227015200A Ceased KR20220062688A (ko) 2015-07-08 2016-07-07 안구 염증 병태의 치료에 사용하기 위한 인테그린 알파4 길항제를 포함하는 제약 조성물

Country Status (21)

Country Link
US (3) US10413535B2 (https=)
EP (1) EP3319639B1 (https=)
JP (2) JP6752276B2 (https=)
KR (2) KR102440162B1 (https=)
CN (1) CN107921136A (https=)
AU (1) AU2016290197B2 (https=)
BR (1) BR112018000112A2 (https=)
CA (1) CA2989522C (https=)
CL (1) CL2018000057A1 (https=)
ES (1) ES2835274T3 (https=)
HK (1) HK1247120A1 (https=)
IL (2) IL256770B (https=)
MA (2) MA42016A1 (https=)
MX (1) MX385229B (https=)
MY (1) MY187552A (https=)
PL (1) PL3319639T3 (https=)
RU (1) RU2018103940A (https=)
TN (1) TN2017000538A1 (https=)
UA (1) UA123728C2 (https=)
WO (1) WO2017006272A1 (https=)
ZA (1) ZA201708601B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165218A1 (en) 2017-03-09 2018-09-13 Allysta Pharmaceuticals, Inc Peptides for dry eye disease
WO2018212846A1 (en) * 2017-05-19 2018-11-22 Ocugen, Inc. Ophthalmic compositions and methods of use
FI3873884T3 (fi) 2018-10-30 2025-02-24 Gilead Sciences Inc 3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
ES3013256T3 (en) 2018-10-30 2025-04-11 Gilead Sciences Inc Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
EP3873605B1 (en) 2018-10-30 2024-10-23 Gilead Sciences, Inc. Compounds for inhibition of alpha4beta7 integrin
JP2022541851A (ja) * 2019-07-26 2022-09-27 アレグロ ファーマシューティカルズ エルエルシー 眼の非滲出型黄斑変性および他の障害を治療するためのペプチド
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
IL302175A (en) * 2020-10-21 2023-06-01 Azura Ophthalmics Ltd Compounds and methods for the treatment of ocular disorders
KR102391198B1 (ko) * 2021-08-27 2022-04-27 한림제약(주) 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828074D0 (en) * 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
GB0014892D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
DK2444079T3 (en) 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
JP2009514969A (ja) * 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
US20130217657A1 (en) * 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Expert Opinion on Therapeutic Patents, 2002, 12(5) 755-757*
Investigative Ophthalmology & Visual Science, 2015, 56(7), 2472*
Investigative Ophthalmology & Visual Science, 2015, 56(7), 4449*

Also Published As

Publication number Publication date
TN2017000538A1 (en) 2019-04-12
MA44935A1 (fr) 2019-08-30
US10751334B2 (en) 2020-08-25
EP3319639B1 (en) 2020-11-18
BR112018000112A2 (pt) 2018-09-04
IL256770B (en) 2021-02-28
KR20220062688A (ko) 2022-05-17
HK1247120A1 (zh) 2018-09-21
ES2835274T3 (es) 2021-06-22
CN107921136A (zh) 2018-04-17
KR20180041122A (ko) 2018-04-23
ZA201708601B (en) 2019-05-29
MA42016A1 (fr) 2018-03-30
MX2017017163A (es) 2018-08-09
CA2989522A1 (en) 2017-01-12
IL280827A (en) 2021-04-29
CL2018000057A1 (es) 2018-06-22
UA123728C2 (uk) 2021-05-26
US20200000786A1 (en) 2020-01-02
JP2020121985A (ja) 2020-08-13
AU2016290197B2 (en) 2021-07-22
IL256770A (en) 2018-03-29
US20180200240A1 (en) 2018-07-19
MY187552A (en) 2021-09-29
AU2016290197A1 (en) 2018-01-04
RU2018103940A3 (https=) 2019-09-03
EP3319639A1 (en) 2018-05-16
RU2018103940A (ru) 2019-08-08
JP6752276B2 (ja) 2020-09-09
PL3319639T3 (pl) 2021-03-08
US20200405703A1 (en) 2020-12-31
JP2018521126A (ja) 2018-08-02
US10413535B2 (en) 2019-09-17
WO2017006272A1 (en) 2017-01-12
MX385229B (es) 2025-03-14
CA2989522C (en) 2022-10-18

Similar Documents

Publication Publication Date Title
KR102440162B1 (ko) 안구 염증 병태의 치료에 사용하기 위한 인테그린 알파4 길항제를 포함하는 제약 조성물
US12496326B2 (en) Ophthalmic composition for treatment of dry eye disease
JP7116490B2 (ja) 眼の炎症性障害および疾患の組合せ処置
US20170290888A1 (en) Compositions and Methods for Treating Inflammatory Conditions of the Ocular Surface
EP4167965A1 (en) Use of high molecular weight hyaluronic acid as ocular transporting vehicle
OA19750A (en) Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions.
Marshall et al. Dry eye disease: focus on prescription therapy
Agrahari et al. Recent patents and emerging therapeutics on ocular inflammation and allergy
HK40113015A (en) Ophthalmic composition for treatment of dry eye disease
Escott et al. Medical Management of CME Associated with Uveitis

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180205

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200703

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220123

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220404

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220123

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220504

PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220404

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220322

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200703

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20220603

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20220504

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220404

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20220322

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200703

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220831

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220831

End annual number: 3

Start annual number: 1

PG1601 Publication of registration